http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102457504-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-163 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate | 2017-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102457504-B1 |
titleOfInvention | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
abstract | The present description relates to a T cell receptor (TCR) that binds to a tumor associated antigen (TAA) for targeting of cancer cells, a cell expressing the same, a method for producing the same, and a method of treating cancer using the same. In particular, the present description relates to TCRs and variants thereof that bind to HLA class I or II molecules with peptides, such as MAG-003 having the amino acid sequence of KVLEHVVRV (SEQ ID NO: 1). The present description also relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to immunotherapy of cancer. The present description also describes tumor-associated T-cell peptide epitopes alone or other tumor-associated peptides that may serve as active pharmaceutical ingredients, for example, in vaccine compositions that promote anti-tumor immune responses or stimulate T cells ex vivo to transfer to a patient. It relates to the combination with Peptides or peptides bound to molecules of the major histocompatibility complex (MHC) may also be targets of antibodies, soluble T cell receptors and other binding molecules. |
priorityDate | 2016-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 876.